Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28156546 | 0.98 | SOAT1 (0.52) | SOAT1TP53MEN1FAAHCYP1A2 | |
| SCHEMBL28156538 | 0.98 | SOAT1 (0.52) | SOAT1TP53MEN1FAAHCYP1A2 | |
| SCHEMBL5571197 | 0.98 | SOAT1 (0.52) | SOAT1TP53MEN1FAAHCYP1A2 | |
| SCHEMBL12048764 | 0.98 | SOAT1 (0.52) | SOAT1TP53MEN1FAAHCYP1A2 | |
| SCHEMBL21207379 | 0.98 | SOAT1 (0.52) | SOAT1TP53MEN1FAAHCYP1A2 | |
| SCHEMBL25491675 | 0.98 | SOAT1 (0.52) | SOAT1TP53MEN1FAAHCYP1A2 | |
| SCHEMBL18978503 | 0.98 | SOAT1 (0.52) | SOAT1TP53MEN1FAAHCYP1A2 | |
| SCHEMBL22803309 | 0.98 | SOAT1 (0.52) | SOAT1TP53MEN1FAAHCYP1A2 | |
| SCHEMBL28269618 | 0.96 | SOAT1 (0.46) | SOAT1TP53MEN1FAAHCYP1A2 | |
| SCHEMBL28155829 | 0.93 | CA2 (0.53) | SOAT1TP53MEN1FAAHCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105971571-B | Method and composition for oil well and/or gas well | 弗洛泰克化学有限责任公司 | 2019-10-15 | — | — | CN | disclosed |
| CN-106837217-B | For oil well and/or the composition and method comprising terpenol of gas well | 弗洛泰克化学有限责任公司 | 2019-07-02 | — | — | CN | disclosed |
| CN-105419750-B | Method and composition for oil well and/or gas well | 弗洛泰克化学有限责任公司 | 2019-03-22 | — | — | CN | disclosed |
| CN-106837217-A | For oil well and/or the composition comprising terpenol and method of gas well | 弗洛泰克化学有限责任公司 | 2017-06-13 | — | — | CN | disclosed |
| US-20100099610-A1 | Transglutaminase Variants with Improved Specificity | NOVO NORDISK HEALTH CARE AG (CH) | 2010-04-22 | — | — | US | disclosed |
| US-20100087371-A1 | Transglutaminase Variants with Improved Specificity | NOVO NORDISK HEALTH CARE AG (CH) | 2010-04-08 | — | — | US | disclosed |
| US-20090318349-A1 | TRANSGLUTAMINASE VARIANTS WITH IMPROVED SPECIFICITY | NOVO NORDISK HEALTH CARE AG (CH) | 2009-12-24 | — | — | US | disclosed |
| US-20090117640-A1 | Transglutaminase Variants with Improved Specificity | NOVO NORDISK HEALTH CARE AG (CH) | 2009-05-07 | — | — | US | disclosed |
| WO-2008102007-A1 | TRANSGLUTAMINASE VARIANTS WITH IMPROVED SPECIFICITY | NOVO NORDISK HEALTH CARE AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008102008-A1 | TRANSGLUTAMINASE VARIANTS WITH IMPROVED SPECIFICITY | NOVO NORDISK HEALTH CARE AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008020075-A1 | TRANSGLUTAMINASE VARIANTS WITH IMPROVED SPECIFICITY | NOVO NORDISK HEALTH CARE AG (DK) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020074-A1 | TRANSGLUTAMINASE VARIANTS WITH IMPROVED SPECIFICITY | NOVO NORDISK HEALTH CARE AG (CH) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007020290-A1 | TRANSGLUTAMINASE VARIANTS WITH IMPROVED SPECIFICITY | NOVO NORDISK HEALTH CARE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099610-A1 | Transglutaminase Variants with Improved Specificity | SHBG, GLMN, GGH | SOAT1 4690/4885TP53 2583/4885MEN1 255/4885 |
| US-20100087371-A1 | Transglutaminase Variants with Improved Specificity | SHBG, GLMN, GGH | SOAT1 4690/4885TP53 2583/4885MEN1 255/4885 |
| US-20090318349-A1 | TRANSGLUTAMINASE VARIANTS WITH IMPROVED SPECIFICITY | SHBG, GLMN, GGH | SOAT1 4690/4885TP53 2583/4885MEN1 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.